[CMV and kidney transplant: prophylaxis and therapy].
Cytomegalovirus (CMV) infection is still an important cause of morbidity and mortality in kidney transplant recipients. Valganciclovir allows prophylaxis and therapy in an outpatient setting in most cases. PV16000, Victor and Impact200 are the double-blind multicenter studies which have introduced valganciclovir in everyday clinical practice. CMV-specific immunoglobulins are being used much less than before, except in the presence of hypogammaglobulinemia. Evaluation of specific CMV immunity with ELISPOT is introducing a promising new test to help clinicians in the management of CMV infection.
Malattie Infettive e Tropicali, Azienda Ospedaliera di Padova, Padova - Italy.
Dino
D
Sgarabotto
Serena
S
Marinello
D018890:Chemoprevention; D003586:Cytomegalovirus Infections / Q000188:drug therapy* / Q000517:prevention & control*; D006801:Humans; D016030:Kidney Transplantation; D011183:Postoperative Complications / Q000188:drug therapy* / Q000517:prevention & control*